You are here

Opioid-Free Alternative for Patients with Musculoskeletal Disorders

Combination Pain Reliever Slated for August 2019 Approval

Galt Pharmaceuticals’ Orphengesic Forte has received a priority review goal date for FDA approval by August 14, 2019. The approval will provide physicians and patients with a non-controlled opioid-free alternative for pain management.

Estimates indicate that 47,600 people died from opioid overdoses in 2017 in the U.S. In addition, from July 2016 to September 2017, there was a 30% increase in the use of opioids.

Orphengesic Forte is an oral, non-controlled, combination muscle-relaxant pain reliever. The tablets contain 50 mg orphenadrine citrate, 770 mg aspirin, and 60 mg caffeine. The drug is indicated for the relief of mild to moderate pain in acute musculoskeletal disorders, in combination with rest and physical therapy.

Source: Business Wire, May 30, 2019

Recent Headlines

Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications